LAUSR

The novel coronavirus disease 2019 (COVID‐19) has become a global health emergency. Early detection and intervention are key factors for improving outcomes in patients with COVID‐19. Real‐time reverse transcriptase polymerase chain reaction‐based molecular assays and antibody for detecting SARS‐CoV‐2 in respiratory specimens are the current reference standard for COVID‐19 diagnosis. Clinical implications of different specimen types for nucleic acid and antibody testing of COVID‐19 in Zhongnan hospital of Wuhan University were analyzed. Compared with health groups, tumor patients had higher rate of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) (+/−) immunoglobulin M (IgM) (+) immunoglobulin G (IgG) (+). The rate of SARS‐CoV‐2 (−) IgM (+) IgG (−) or SARS‐CoV‐2 (−) IgM (−) IgG (+) in female was significantly higher than that in male. These results can help governments to take screening measures to prevent the COVID‐19 pandemic again.